Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
Tiandan Xiang, Boyun Liang, Hua Wang, Xufeng Quan, Shengsong He, Helong Zhou, Yongwen He, Dongliang Yang, Baoju Wang, Xin Zheng
Abstract
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, has become a major global public health threat. Although significant advances have been made in developing and applying different vaccines in clinical trials [ 1 , 2 ], data are limited on the safety and efficacy of the inactivated vaccine in patients with chronic liver disease [ 3 ]. Recent studies have preliminarily described the safety and immunogenicity of SARS-CoV-2 vaccines in patients with nonalcoholic fatty liver disease and in liver transplant recipients [ 4 , 5 ]. However, to date, there is no detailed information on the SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B (CHB) infection. It has been reported that CHB patients have impaired immune systems [ 6 ]. Hence, whether immunocompromised CHB patients within the different clinical stages can be safely vaccinated with the various types of SARS-CoV-2 vaccines and produce an effective immune response remains unclear. Our study aims to provide a comprehensive analysis from different clinical dimensions to characterize the safety and immunogenicity of SARS-CoV-2 inactivated vaccines (BBIBP-CorV, CoronaVac, or WIBP-CorV) within this specific patient population.